Jefferies initiated coverage of Crescent Biopharma (CBIO) with a Buy rating and $26 price target Crescent is a preclinical-stage oncology company with CR-001 as its lead asset, the analyst tells investors in a research note. Jefferies believes in the PD-(L)1xVEGF class and sees an “intriguing” risk/reward at current share levels.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CBIO: